Bristol Myers Squibb agreed to acquire Orbital Therapeutics for $1.5 billion in cash, the company announced, marking a strategic move into in vivo CAR‑T platforms. Orbital is developing in vivo CAR‑T approaches intended to deliver CAR constructs directly in the body, avoiding ex vivo cell manufacturing. BMS said the deal augments its cell therapy pipeline and could simplify access and logistics relative to current autologous CAR‑T products. The acquisition positions BMS to compete in the emerging field of direct in‑body cell engineering alongside other players receiving government and private investment.